ID: ALA554154

Max Phase: Preclinical

Molecular Formula: C35H32ClN3O2

Molecular Weight: 562.11

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)CC1(CN2CCc3c(c4ccccc4n3Cc3cccc(/C=C/c4ccc5ccc(Cl)cc5n4)c3)C2)CC1

Standard InChI:  InChI=1S/C35H32ClN3O2/c36-27-11-9-26-10-13-28(37-31(26)19-27)12-8-24-4-3-5-25(18-24)21-39-32-7-2-1-6-29(32)30-22-38(17-14-33(30)39)23-35(15-16-35)20-34(40)41/h1-13,18-19H,14-17,20-23H2,(H,40,41)/b12-8+

Standard InChI Key:  BRXAPWZPFXXMER-XYOKQWHBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 562.11

Molecular Weight (Monoisotopic): 561.2183

AlogP: 7.67

#Rotatable Bonds: 8

Polar Surface Area: 58.36

Molecular Species: ACID

HBA: 4

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 4.07

CX Basic pKa: 7.84

CX LogP: 4.62

CX LogD: 4.52

Aromatic Rings: 5

Heavy Atoms: 41

QED Weighted: 0.21

Np Likeness Score: -0.67

References

1. Bonjoch J, Diaba F, Pagès L, Pérez D, Soca L, Miralpeix M, Vilella D, Anton P, Puig C..  (2009)  Synthesis and structure-activity relationships of gamma-carboline derivatives as potent and selective cysLT(1) antagonists.,  19  (15): [PMID:19505824] [10.1016/j.bmcl.2009.05.094]

Source

Source(1):

• Scientific Literature